NovaBay Pharmaceuticals, Inc. (NBY)
NYSEAMERICAN: NBY · IEX Real-Time Price · USD
0.675
-0.005 (-0.68%)
At close:
May 26, 2023, 4:00 PM
0.679
+0.004 (0.59%)
Pre-market:
May 30, 2023, 8:02 AM EDT
NovaBay Pharmaceuticals Stock Forecast
Stock Price Forecast
There is currently no analyst price target forecast available for NBY stock.
Analyst Consensus: n/a
Analyst Ratings
There are currently no analyst ratings available for NBY.
Recommendation Trends
| Rating | Dec '21 | Jan '22 | Feb '22 | Mar '22 | Apr '22 | May '22 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 1 | 1 | 1 | 1 | 1 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 1 | 1 | 1 | 1 | 1 | 0 |
Financial Forecast
Revenue This Year
15.15M
from 14.40M
Increased by
5.18%
Revenue Next Year
20.20M
from 15.15M
Increased by
33.33%
EPS This Year
-2.92
from -10.10
EPS Next Year
-0.86
from -2.92
| Year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 12.51M | 6.60M | 9.93M | 10.20M | 14.40M | 15.15M | 20.20M | 42.21M |
| Revenue Growth | -31.39% | -47.24% | 50.54% | 2.72% | 41.16% | 5.18% | 33.33% | 108.95% |
| EPS | -16.10 | -16.80 | -10.85 | -5.26 | -10.10 | -2.92 | -0.86 | 0.10 |
| EPS Growth | - | - | - | - | - | - | - | - |
| No. Analysts | - | - | - | - | - | 2 | 2 | 2 |
Revenue Forecast
| Revenue | 2023 | 2024 | 2025 |
|---|---|---|---|
| High | 15.8M | 21.0M | 43.9M |
| Avg | 15.2M | 20.2M | 42.2M |
| Low | 14.7M | 19.6M | 41.0M |
Revenue Growth
| Revenue Growth | 2023 | 2024 | 2025 |
|---|---|---|---|
| High | 9.3%
| 38.6%
| 117.2%
|
| Avg | 5.2%
| 33.3%
| 109.0%
|
| Low | 2.1%
| 29.4%
| 102.7%
|
EPS Forecast
| EPS | 2023 | 2024 | 2025 |
|---|---|---|---|
| High | -3.03 | -0.89 | 0.11 |
| Avg | -2.92 | -0.86 | 0.10 |
| Low | -2.83 | -0.83 | 0.10 |
EPS Growth
| EPS Growth | 2023 | 2024 | 2025 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.